Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16964268 | 0.80 | MPO (0.39) | CYP1A2LRRK2MPOXDHABL1 | |
| SCHEMBL14707646 | 0.78 | MPO (0.46) | CYP1A2LRRK2MPOHTTCYP11B2 | |
| SCHEMBL16458019 | 0.78 | MPO (0.43) | CYP1A2LRRK2MPOXDHHTT | |
| SCHEMBL24977549 | 0.78 | MPO (0.38) | CYP1A2LRRK2MPOHTTCYP11B2 | |
| SCHEMBL31332918 | 0.77 | CYP1A2 (0.38) | CYP1A2LRRK2NR3C1HTTKMT2A | |
| SCHEMBL31332962 | 0.76 | CYP1A2 (0.37) | CYP1A2LRRK2NR3C1HTTCYP11B2 | |
| SCHEMBL30134021 | 0.74 | MPO (0.36) | CYP1A2LRRK2MPOHTTKMT2A | |
| SCHEMBL1195342 | 0.74 | CYP11B2 (0.41) | CYP1A2LRRK2MPOCYP11B2KMT2A | |
| SCHEMBL6251041 | 0.73 | POLB (0.53) | HTTKMT2AMEN1 | |
| SCHEMBL24483790 | 0.72 | CYP11B2 (0.45) | CYP1A2LRRK2MPOCYP11B2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820773-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169650-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | CYP1A2 86/4885LRRK2 2475/4885MPO 890/4885 |
| US-11820773-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | CYP1A2 86/4885LRRK2 2475/4885MPO 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.